Related Experiment Video
Updated: Jan 10, 2026
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
P2Y12-Inhibitor Clopidogrel Promotes Collateral Artery Growth in a Murine Hindlimb Model of Arteriogenesis
Katharina Elbs1,2, Lisa Bobrowski1,2, Christoph Arnholdt1,2,3
1Institute of Surgical Research at the Walter-Brendel-Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Insights
Clopidogrel enhances arteriogenesis, the growth of natural bypasses around blocked arteries. This drug boosts vascular cell proliferation by improving immune cell interactions and regenerative inflammation.
Area of Science:
- Cardiovascular Biology
- Inflammation Research
- Vascular Biology
Background:
- Clopidogrel, a P2Y12 receptor inhibitor, is a common antiplatelet therapy for cardiovascular occlusive diseases.
- Its specific role in vascular remodeling, particularly arteriogenesis, is not well understood.
- Platelets are known to mediate sterile inflammation crucial for arteriogenesis.
Purpose of the Study:
- To investigate the effect of P2Y12 inhibition by Clopidogrel on arteriogenesis.
- To understand the mechanisms by which Clopidogrel might influence collateral artery growth.
Main Methods:
- Utilized a murine hindlimb model to study arteriogenesis.
- Quantified collateral artery growth using laser-Doppler perfusion and immunohistology.
- Assessed immune cell recruitment, activation, and platelet-leukocyte interactions via flow cytometry and histology.
Main Results:
- Clopidogrel treatment improved perfusion recovery in the hindlimb model.
- Enhanced vascular cell proliferation was observed in Clopidogrel-treated mice.
- Increased platelet-leukocyte interactions, mast cell degranulation, and regenerative macrophage accumulation were noted.
Conclusions:
- Clopidogrel treatment promotes arteriogenesis by enhancing regenerative inflammation.
- This process involves increased vascular cell proliferation and specific immune cell dynamics.
- P2Y12 inhibition could be a therapeutic strategy to promote natural bypass growth in cardiovascular occlusive diseases.
Abstract:
Background/Objectives: Clopidogrel is a P2Y12 receptor inhibitor commonly used as antiplatelet therapy for patients with cardiovascular occlusive diseases. However, its role in vascular remodeling remains poorly understood. Platelets orchestrate the sterile inflammation in arteriogenesis, an endogenous process to bypass an occluded artery. Therefore, we investigated the impact of P2Y12-inhibition by Clopidogrel on arteriogenesis. Methods: In this study, we utilized a well-established murine hindlimb model of arteriogenesis. To quantify the growth of collateral arteries, we employed laser-Doppler perfusion measurements and immunohistological analysis of growing compared to resting collateral arteries. Additional immunofluorescence and histological stains were conducted to assess immune cell recruitment and activation. Whole-blood flow cytometry was performed to analyze platelet-leukocyte interactions, and complete blood counts were obtained to quantify leukocyte and platelet numbers. Results: The findings of this study demonstrate that Clopidogrel promotes perfusion recovery following the induction of arteriogenesis compared to controls, attributed to elevated levels of proliferating vascular cells. Furthermore, compared to controls, Clopidogrel treatment significantly enhanced platelet-leukocyte interactions, increasing perivascular mast cell recruitment and degranulation, finally resulting in regenerative macrophage accumulation required for collateral artery growth. Conclusions: Clopidogrel treatment boosts arteriogenesis by enhancing the local regenerative inflammation relevant for vascular cell proliferation. Therefore, P2Y12 inhibition may represent a therapeutic option to effectively promote natural bypass growth in patients with cardiovascular occlusive diseases.
